NXTCNextcure Inc

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB PR Newswire NEW YORK, July 22, 2026 NEW YORK, July 22, 2026 /PRNewswire...

Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

NextCure will merge with Avere in a $320 million exchange to advance oral IL-23 therapy AVR-001 and list the combined company as AVRX.read more...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) PR Newswire NEW YORK, July 14, 2026 NEW YORK, July 14, 2026 /PRNewswire/ -- Class Action...

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) sharesread more...

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, July 14, 2026 MILWAUKEE, July 14, 2026...

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company.Halper Sadeh encourages NextCure...

Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock movedread more...

NextCure (NASDAQ:NXTC) is making one of the most dramatic strategic pivots seen in biotechnology this year, announcing an all-stock merger with privately held Avere Therapeutics that will effectively transform the company into a new publicly traded autoimmune disease developer. Upon closing, the combined company will operate as Avere Therapeutics and trade under the new NASDAQ ticker AVRX, shifting its primary focus from oncology to inflammatory diseases driven by the IL-23 pathway.